* Frequency Therapeutics Inc FREQ.OQ FREQ.O is expected
to show no change in quarterly revenue when it reports
results on May 2 (estimated).
*
* Refinitiv's mean analyst estimate for Frequency
Therapeutics
Inc is for a loss of 42 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 2.5%
in the last three months.
* Wall Street's median 12-month price target for Frequency
Therapeutics Inc is $4, above its last closing price of $0.40.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.57 -0.63 -0.49 Beat 22.3
Sep. 30 2022 -0.56 -0.57 -0.55 Beat 3.4
Jun. 30 2022 -0.70 -0.67 -0.61 Beat 9.4
Mar. 31 2022 -0.62 -0.63 -0.67 Missed -5.5
Dec. 0.59 0.15 -0.62 Missed -506.8
31 2021
Sep. 30 2021 -0.52 -0.57 -0.73 Missed -27.2
Jun. 30 2021 -0.51 -0.51 -0.52 Missed -2.3
Mar. 31 2021 -0.28 -0.28 -0.60 Missed -116.9
This summary was machine generated April 29 at 02:11 GMT. All
figures in US dollars unless otherwise stated